SAN DIEGO, April 13, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”),...
EPIDOLEX encore presentations highlight long-term safety and efficacy data in patients with tuberous sclerosis complex (TSC) and other treatment-resistant epilepsies...
– Appointment strengthens leadership team as the Company readies for potential global odevixibat launch and progresses multiple clinical development programs...
Collaboration combines Senti Bio’s leading-edge gene circuit technology platform and high-throughput synthetic promoter design capabilities with Spark Therapeutics’ investigational gene...
Phase 1b/2a Study Expected to Begin In 2Q 2021DELRAY BEACH, Fla., April 13, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc....
- Collaboration combines Senti Bio’s leading-edge gene circuit technology platform and high-throughput synthetic promoter design capabilities with Spark Therapeutics’ investigational...
Recently Commenced Patient Enrollment in Phase 1/2 CAReS Study of ART27.13 in the UK Reported Positive Pre-Clinical Data Associated with...
Thomasville, GA, April 13, 2021 (GLOBE NEWSWIRE) -- Industry Source Consulting, Inc. (OTC: INSO), is pleased to announce that the...
Study meets primary safety endpoint; positive secondary efficacy assessments support potential benefit from Lomecel-B Decline in cognitive function slower in...
- Ongoing ADAIR SEAL study on target for pivotal data readout in second half of 2021- Target NDA filing in...
Loughborough, England, April 13, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology...
Company announcement – No. 21/ 2021 Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and...
Helsinn announces poster presentation at Academy of Managed Care Pharmacy (AMCP) 2021 Virtual Meeting evaluating healthcare resource utilization in CINV...
MARKHAM, Ontario, April 13, 2021 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced today that it...
Phase One Efixii SaaS License for 44M Grams for the 2022 HarvestVANCOUVER, British Columbia, April 13, 2021 (GLOBE NEWSWIRE) --...
Poster Presentation Highlights the Unmet Patient Need and Medical Cost Burden Associated with Hepatitis B Infection Healthcare Costs Associated with...
This Pre-Series A Funding will accelerate the growth of ImpriMed’s AI-powered predictive tool that identifies which anti-cancer drugs are most...
BOSTON, April 13, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a biopharmaceutical company focused on the development of innovative,...
ANAHEIM, CA, April 13, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (“BioCorRx” or the “Company”), a...
WINNIPEG, Manitoba, April 13, 2021 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), is pleased...